Screener
McKesson MCK Oncology & Multispecialty — Total segment depreciation and amortization
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 |
|---|---|---|
| Income before income taxes | $1,308 | $1,051 |
| Segment depreciation and amortization (7) | ||
| North American Pharmaceutical | $39 | $32 |
| Oncology & Multispecialty | 66 | 42 |
| Prescription Technology Solutions | 19 | 21 |
| Medical-Surgical Solutions | 26 | 22 |
| Other | — | 3 |
| Corporate | 45 | 37 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's oncology & multispecialty — total segment depreciation and amortization?
- McKesson (MCK) reported oncology & multispecialty — total segment depreciation and amortization of $66M in Q2 2026.
- How has McKesson's oncology & multispecialty — total segment depreciation and amortization changed year-over-year?
- McKesson's oncology & multispecialty — total segment depreciation and amortization increased by 57.1% year-over-year, from $42M to $66M.
- What is the long-term trend for McKesson's oncology & multispecialty — total segment depreciation and amortization?
- Over 2 years (2024 to 2026), McKesson's oncology & multispecialty — total segment depreciation and amortization has grown at a 32.4% compound annual growth rate (CAGR), from $137M to $240M.
- What does oncology & multispecialty — total segment depreciation and amortization mean?
- The total non-cash expense allocated to the Oncology and Multispecialty segment related to the systematic write-down of tangible and intangible assets. This reflects the consumption of capital investments over time, such as distribution infrastructure, technology platforms, or acquired customer relationships. It is a critical component for calculating segment-level EBITDA and cash flow.
Ask your AI about McKesson's oncology & multispecialty — total segment depreciation and amortization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude